We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
+$224M
Cap. Flow %
9.21%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.86%
2 Healthcare 14.52%
3 Energy 1.33%
4 Technology 0.46%
5 Materials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
226
CALL
DELISTED
Amicus Therapeutics
FOLD
$1.02M 0.04%
730
+97
+15% +$1.52K
CAPR icon
227
Capricor Therapeutics
CAPR
$498M
$1.01M 0.04%
25,045
-795
-3% -$35.4K
EXEL icon
228
CALL
Exelixis
EXEL
$14.1B
$1M 0.04%
1,783
-493
-22% -$2.68K
CNSY
229
Cerenome
CNSY
$16.1M
$1M 0.04%
1
-1
-50% -$1.17M
ARIA
230
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$987K 0.04%
169,000
+3,730
+2% +$28.7K
ARIA
231
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$987K 0.04%
1,690
+91
+6% +$701
BCRX icon
232
BioCryst Pharmaceuticals
BCRX
$2.09B
$985K 0.04%
+86,395
New +$1.15M
INSM icon
233
CALL
Insmed
INSM
$26.2B
$949K 0.04%
511
+185
+57% +$4.62K
LRMR icon
234
PUT
Larimar Therapeutics
LRMR
$406M
$946K 0.04%
25
– –
ASRT
235
DELISTED
Assertio
ASRT
$943K 0.04%
+833
New +$1.42M
NVRO
236
CALL
DELISTED
NEVRO CORP.
NVRO
$942K 0.04%
+203
New +$9.84K
ANAC
237
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$942K 0.04%
+8,000
New +$1.04M
NTRA icon
238
Natera
NTRA
$50.6B
$939K 0.04%
+86,523
New +$1.47M
HTWR
239
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$915K 0.04%
+17,500
New +$1.33M
GWPH
240
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$914K 0.04%
100
-50
-33% -$5.56K
CSBR icon
241
Champions Oncology
CSBR
$66.4M
$893K 0.04%
+169,397
New +$1.11M
PTLA
242
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$878K 0.04%
+206
New +$9.94K
ADXS
243
DELISTED
Advaxis Inc
ADXS
$877K 0.04%
+5,713
New +$1.38M
ADXS
244
PUT
DELISTED
Advaxis Inc
ADXS
$872K 0.04%
57
+11
+24% +$2.66K
TNXP icon
245
CALL
Tonix Pharmaceuticals
TNXP
$199M
– –
0
– –
ACGN
246
CALL
DELISTED
Aceragen Inc
ACGN
$857K 0.04%
2
– –
MBOT icon
247
Microbot Medical
MBOT
$96.7M
$856K 0.04%
1,259
-48
-4% -$36.5K
SGYPW
248
PUT
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$855K 0.04%
1,613
-1,523
-49% -$5.36K
CYNA
249
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$845K 0.03%
52,169
+32,866
+170% +$534K
NGNE icon
250
Neurogene
NGNE
$674M
$844K 0.03%
+3,000
New +$691K
8 9
10
11 12

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.